. . . "beta-Methasone alcohol"@en . . . . . . . . . . . . . . . . "9-Fluoro-16\u03B2-methylprednisolone"@en . . . . . . . . . . . . . . . . . . "Betamethasonvalerat Mikron"@en . . . . . . . . . . . . . . . . . "16\u03B2-Methyl-1,4-pregnadiene-9\u03B1-fluoro-11\u03B2,17\u03B1,21-triol-3,20-dione"@en . . . . . . . . . "Humans and other mammals"@en . "64%"@en . . "9alpha-Fluoro-16beta-methylprednisolone"@en . . . "378-44-9"@en . . . . . . . "Fernando AHUMADA AYALA, \"SKIN-CARE PREPARATIONS CONTAINING MUPIROCIN AND BETAMETHASONE DIPROPIONATE.\" U.S. Patent US20100063015, issued March 11, 2010."@en . . . . . . "Betamethasone"@en . . . . . . . . . . . . . . . . . . . . . . "approved"@en . . . . . . . . . . . . . . . . . . . . "5.6 hours"@en . . . . . . "Betamethasonum"@en . . . . . . . . . . . . . "Betadexamethasone"@en . . . . "Topical use (cream, lotion and ointment): for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Topical use (foam): relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp
Systemic use: for the treatment of edocrine disorders, rheumatic disorders, collagen diseases, dermatological diseases, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, tuberculous meningitis and trichinosis."@en . . . . . . "Betamethasone is a glucocorticoid receptor agonist. This leads to changes in genetic expression once this complex binds to the GRE. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Betamethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin."@en . "Minimal if applied topically."@en . . . . . "9-Fluoro-16beta-methylprednisolone"@en . . . . "9\u03B1-Fluoro-16\u03B2-methylprednisolone"@en . . "Rinderon"@en . . . . . . " "@en . . "Betamethasone"@en . . "Betametasona"@en . . "16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione"@en . . . . . . . . . . . . . . . . . . . . . . . . "Symptoms of overdose include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria."@en . . . . . . . . . . . . . . . . "Take with food to reduce irritation."@en . . . "A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)"@en . . . . . . . . . . . . . . . . . . . " "@en . . .